5963-60-0

Basic information

• Product Name: H-GLU(ANILIDE)-OH
• Synonyms: L-GLUTAMIC ACID GAMMA-ANILIDE;H-GLU(ANILIDE)-OH;(S)-2-AMINO-5-ANILIDE-5-OXOPENTANOIC ACID;L-GLUTAMIC ACID-Y-ANILIDE;H-Gln(Ph)-OH;(S)-2-Amino-4-[(phenylamino)carbonyl]butanoic acid;2-Aminoglutalanilic acid;N5-Phenyl-L-glutamine
• CAS NO: 5963-60-0
• Molecular Formula: C₁₁H₁₄N₂O₃
• Molecular Weight: 222.24
• Mol File: 5963-60-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Store at RT.
• CAS DataBase Reference: H-GLU(ANILIDE)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: H-GLU(ANILIDE)-OH(5963-60-0)
• EPA Substance Registry System: H-GLU(ANILIDE)-OH(5963-60-0)

Safety Data

• Hazardous Substances Data: 5963-60-0(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Upstream product

• 1535-57-5 (S)-N-(2,6-dioxotetrahydro-2H-pyran-3-yl)-2,2,2-trifluoroacetamide 
• 4816-80-2 N-tosyl-L-glutamic acid 
• 21957-65-3 1-(4'-methylbenzenesulfonyl)-5-oxopyrrolidine-2-carboxylic acid 
• 151838-23-2 (S)-4-(2-Chlorocarbonyl-ethyl)-5-oxo-oxazolidine-3-carboxylic acid 2,2,2-trichloro-ethyl ester 
• 131451-20-2 (S)-4-(2-Carboxy-ethyl)-5-oxo-oxazolidine-3-carboxylic acid 2,2,2-trichloro-ethyl ester 
• 62-53-3 aniline 
• 23632-67-9 (S)-3-[3-(benzyloxycarbonyl)-5-oxooxazolidin-4-yl]propanoic acid 
• 58456-26-1 (S)-4-<2'-(Chloroformyl)ethyl>-5-oxooxazolidin-3-carbonsaeure-benzylester 
• 1155-62-0 N-benzyloxycarbonyl-L-glutamic acid 
• 56-86-0 L-glutamic acid 
• 848215-07-6 5-oxo-4-[2-(phenylcarbamoyl)ethyl]oxazolidine-3-carboxylic acid benzyl ester 
• 110336-85-1 N²-benzyloxycarbonyl-N⁵-phenyl-L-glutamine 
• 25830-77-7 N-phthaloyl-L-glutamic anhydride 
• 7460-91-5 NCS 400401 

Downstream Products

• 102-14-7 N-phenyl-succinamic acid 

Relevant articles and documents

A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP)

Disclosed are novel compositions and methods of using the same for the treatment of Erythropoiefic protoporphyria (EPP) and X-linked protoporphyria (XLP). Disclosed are methods and compositions related to treating Erythropoietic protoporphyria and X-linked protoporphyria. Also described are therapeutic agents that can inhibit ABCG2. For example, provided herein are therapeutic agents defined by Formula I.

A convenient method of protection and mild deprotection of α-aminoacid group for the synthesis of functional α-aminoacids

Functionalisation of β or γ carboxyl group of aspartic and glutamic acids with labile substituents was performed via the use of N-trichloroethoxycarbonyl-5-oxazolidinone as protective group.